AI Summary
InterCure's 2025 results show significant revenue growth of 13%, driven by a robust recovery and strong operational performance. The company turned a corner with positive cash flow and increased Adjusted EBITDA, further supported by international market expansion and strategic partnerships.
Sentiment Rationale
Improved financial metrics, strategic partnerships, and strong recovery indicate likely investor confidence, and historical patterns show similar recoveries often lead to price appreciation.
Trading Thesis
Consider buying INCR for long-term growth as recovery signals improve fundamentals.
Market-Moving
- Current cash flow improvements suggest ongoing financial health and stability.
- New product launches may expand market share and revenue potential in 2026.
- Continued compensation from Israeli authorities could enhance cash reserves significantly.
- International expansion into Germany signals growth opportunities in emerging markets.
Key Facts
- InterCure reported NIS 270 million in revenue for 2025, up 13% from 2024.
- Adjusted EBITDA increased 90%, reaching NIS 47 million, marking 12 consecutive profitable halves.
- The company achieved positive operating cash flow of NIS 17 million after negative cash flow in 2024.
- InterCure launched over 75 new products and is expanding into international markets, including Germany.
- In 2025, InterCure received NIS 82 million in war-related compensation, aiding recovery.
Companies Mentioned
- Purplefarm: InterCure's partnership with Purplefarm enhances product distribution capabilities.
- Cannasoul R&D Ltd. (N/A): Acquisition of 28% stake supports InterCure's R&D efforts and market positioning.
- Botanico Ltd. (ISHI): Acquisition expected to bolster genetics and cultivation capabilities.
Corporate Developments
This announcement falls under 'Corporate Developments' as it highlights financial performance and strategic partnerships crucial for future growth, positioning InterCure favorably in the competitive cannabis sector.